Mary Wilson
Well-known member
March 1, 2023
DOI: 10.1056/NEJMc2216233
To the Editor:
Several B.1.1.529 (omicron) sub- variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are emerging and have become the dominant strains, such as BF.7, BQ.1, BQ.1.1, and XBB. These variants contain more mutations in the spike protein receptor- binding domain (RBD) than the BA.2 and BA.5 strains (Fig. 1A). Therefore, the potential of these omicron subvariants for immune evasion is a concern.
The coronavirus disease 2019 (Covid-19) vac- cines with inactivated virus (CoronaVac and BBIBP-CorV) and the ZF2001 protein subunit vaccine1 have been widely used in China and many other countries. In this study, we obtained serum samples from vaccinees (age range, 18 to 59 years) who had received three homologous doses of ZF2001 (the ZF2001 group, 16 partici- pants) or inactivated vaccine (the inactivated- vaccine group, 16 participants) or two doses of inactivated vaccine plus a booster dose of ZF2001 (the heterologous-boost group, 16 participants) (Fig. S1 in the Supplementary Appendix, avail- able with the full text of this letter at NEJM.org). ...
https://www.nejm.org/doi/full/10.10...+DM2076332_NEJM_Non_Subscriber&bid=1438415850
DOI: 10.1056/NEJMc2216233
To the Editor:
Several B.1.1.529 (omicron) sub- variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are emerging and have become the dominant strains, such as BF.7, BQ.1, BQ.1.1, and XBB. These variants contain more mutations in the spike protein receptor- binding domain (RBD) than the BA.2 and BA.5 strains (Fig. 1A). Therefore, the potential of these omicron subvariants for immune evasion is a concern.
The coronavirus disease 2019 (Covid-19) vac- cines with inactivated virus (CoronaVac and BBIBP-CorV) and the ZF2001 protein subunit vaccine1 have been widely used in China and many other countries. In this study, we obtained serum samples from vaccinees (age range, 18 to 59 years) who had received three homologous doses of ZF2001 (the ZF2001 group, 16 partici- pants) or inactivated vaccine (the inactivated- vaccine group, 16 participants) or two doses of inactivated vaccine plus a booster dose of ZF2001 (the heterologous-boost group, 16 participants) (Fig. S1 in the Supplementary Appendix, avail- able with the full text of this letter at NEJM.org). ...
https://www.nejm.org/doi/full/10.10...+DM2076332_NEJM_Non_Subscriber&bid=1438415850